Trulicity Manufacturer Copay Program: What Women Need to Know About Affording Dulaglutide

What Does Trulicity Actually Cost Without Insurance?

The cash price for Trulicity is steep. A one-month supply of dulaglutide averages around $931 at U.S. Retail pharmacies as of 2025, though prices vary by dose (0.75 mg, 1.5 mg, 3 mg, or 4.5 mg weekly) and by pharmacy. For context, the FDA-approved dose range for type 2 diabetes starts at 0.75 mg weekly and can go up to 4.5 mg weekly, and higher doses carry higher list prices.

For women managing type 2 diabetes, obesity-related metabolic disease, or conditions like polycystic ovary syndrome (PCOS), that monthly cost is simply not sustainable without some form of coverage or assistance.

Why Women Are More Likely to Feel the Cost Burden

Women with PCOS, a condition affecting 8 to 13 percent of reproductive-age women worldwide, are increasingly being prescribed GLP-1 receptor agonists like dulaglutide off-label to address insulin resistance, weight, and androgen excess. Because PCOS is not always the primary ICD-10 code on a claim, insurers sometimes deny GLP-1 coverage, leaving women to pay cash.

Women also carry a disproportionate burden of thyroid disease, autoimmune conditions, and postpartum metabolic shifts that may require multiple concurrent medications, stretching budgets further. Access to affordable GLP-1 therapy is not a minor inconvenience for this population. It is a real clinical barrier.

How the Lilly Trulicity Manufacturer Copay Program Works

Eli Lilly offers a savings card program for Trulicity. Eligible commercially insured patients may pay as little as a reduced copay per fill, with Lilly covering a portion of the remaining cost up to a monthly cap. The specifics of the cap, the per-fill patient cost, and the eligibility rules change periodically, sometimes without wide public notice.

Copay programs change frequently. Treat any figure in this article as a starting reference, not a guarantee. Always confirm current terms at lilly.com or by calling Lilly at 1-800-545-5979 before your next fill.

Who Qualifies for the Lilly Savings Card

To qualify for most manufacturer copay programs, including Lilly's, you generally need to meet all of the following:

• Have commercial (private) health insurance that covers Trulicity, even partially
• Not be enrolled in a federal or state government insurance program (Medicare Part D, Medicaid, TRICARE, or similar)
• Be a U.S. Resident
• Have a valid prescription from a licensed prescriber

The card is not available to uninsured patients through this particular program. If you are uninsured, scroll to the section on alternative programs below.

How to Activate the Card

1. Visit lilly.com and search "Trulicity savings" or ask your pharmacist to look up the current Lilly savings card.
2. Enroll online or by phone before your first fill.
3. Present the card or the digital code at your pharmacy at pickup.
4. Reactivate or re-verify eligibility each calendar year, as programs typically reset in January.

Your pharmacist can also run the card through the pharmacy benefit system alongside your insurance, which sometimes generates a better price than either alone.

Trulicity Insurance Coverage: What to Expect and How to Fight a Denial

Insurance coverage for dulaglutide varies enormously by plan. Most commercial plans cover Trulicity for type 2 diabetes with a prior authorization requirement. Coverage for weight management indications is less consistent because dulaglutide is not FDA-approved specifically for chronic weight management the way semaglutide 2.4 mg (Wegovy) is.

Prior Authorization: What Your Prescriber Needs to Document

Your prescriber typically needs to show:

• A confirmed diagnosis of type 2 diabetes (most reliable route to approval)
• Documentation that you have tried and failed, or have a contraindication to, metformin or another first-line agent
• A current HbA1c, fasting glucose, or other metabolic marker
• Your weight and BMI if weight is a secondary justification

For women with PCOS, your prescriber may need to include documentation of insulin resistance (fasting insulin, HOMA-IR, or glucose tolerance testing) and the clinical rationale for GLP-1 use. The ACOG Committee Opinion on PCOS management does not specifically endorse dulaglutide, but it supports treatment of insulin resistance as a core PCOS target, which gives your prescriber a clinical foundation for the request.

Appealing a Denial

If your insurer denies the prior authorization:

• Request the denial in writing with the specific reason code.
• Ask your prescriber to submit a peer-to-peer review with a physician at the insurance company.
• File a formal appeal citing any relevant guideline or published evidence your prescriber provides.
• Contact your state insurance commissioner if the internal appeal fails.

Denials are not final. Many are overturned on first appeal when documentation is thorough.

Alternative Ways to Afford Trulicity

Lilly Cares Foundation Patient Assistance Program

If you are uninsured or underinsured and your household income falls below a certain threshold (Lilly updates these income limits regularly), you may qualify for the Lilly Cares Foundation, which can provide Trulicity at no cost. This is a separate program from the commercial copay card and does accept patients without insurance.

NeedyMeds and Other Third-Party Resources

NeedyMeds, RxAssist, and similar nonprofit clearinghouses maintain updated databases of manufacturer assistance programs and state pharmaceutical assistance programs. These can be searched by drug name and income level.

GoodRx and Pharmacy Discount Cards

GoodRx and similar platforms negotiate discounted cash prices at participating pharmacies. The price is still high for dulaglutide compared to generic alternatives, but for a one-time or short-term fill while waiting for insurance approval, a GoodRx coupon can reduce the cash price modestly at some pharmacies.

Switching to a GLP-1 With More Access Options

For women who cannot afford Trulicity and are not finding adequate assistance, it is worth asking your prescriber whether semaglutide (Ozempic for diabetes, Wegovy for weight) might be clinically appropriate. Compounded semaglutide from licensed 503B outsourcing facilities became widely available during the FDA shortage period and, depending on updated FDA shortage status, may still carry a significantly lower cost. Compounded dulaglutide is not currently available through licensed 503B compounders in the same way, which is a meaningful cost distinction.

A useful way to think about GLP-1 access by insurance pathway:

| Situation | Best First Step | |---|---| | Commercial insurance, Trulicity covered | Lilly savings card + prior auth | | Commercial insurance, Trulicity denied | Appeal + peer-to-peer review | | Medicare Part D | Lilly copay card NOT eligible; check Extra Help / LIS | | Uninsured, income <400% FPL | Lilly Cares Foundation PAP | | Uninsured, any income | GoodRx cash price + Lilly Cares application | | PCOS, off-label use | Document insulin resistance; appeal if denied |

Sex-Specific Physiology: How Hormones and Life Stage Affect Dulaglutide

Dulaglutide's pharmacokinetics in women differ in ways that matter clinically. Body weight affects GLP-1 receptor agonist exposure, and because women on average have a higher percentage of body fat relative to lean mass than men, subcutaneous absorption kinetics may differ slightly, though the AWARD clinical trial program that established dulaglutide's efficacy and safety enrolled both sexes without reporting sex-stratified PK data in the primary publications. This is an evidence gap you deserve to know about.

Reproductive Years and the Menstrual Cycle

GLP-1 receptor agonists, including dulaglutide, slow gastric motility. This can worsen nausea and vomiting during the luteal phase and early pregnancy, when progesterone already slows gut transit. Women in their reproductive years who experience cyclical GI symptoms may notice that dulaglutide side effects feel worse in the week before their period.

Dulaglutide may also affect the absorption of oral contraceptives by delaying gastric emptying. The Trulicity prescribing information notes that oral medications should be taken with caution in patients using dulaglutide because of this effect on gastric emptying. If you take an oral combined contraceptive, take it consistently at a time that minimizes this interaction, ideally away from your weekly injection day, and discuss the timing with your prescriber.

Perimenopause and Menopause

Perimenopause brings a shift toward central adiposity and worsening insulin resistance, even in women with no prior metabolic disease. GLP-1 therapy is increasingly used in this life stage to address weight gain and glucose dysregulation. Data from the Women's Health Initiative have established that metabolic risk accelerates in the menopausal transition, creating a window where GLP-1 therapy may offer meaningful benefit.

No large trial has specifically enrolled perimenopausal or postmenopausal women to study dulaglutide's effects on menopausal symptom burden, weight, or cardiovascular risk in isolation. This is another evidence gap. What is known is that the REWIND trial, which studied dulaglutide 1.5 mg weekly in patients with type 2 diabetes, demonstrated a 12 percent reduction in major adverse cardiovascular events compared to placebo over a median 5.4 years of follow-up. Women made up 46 percent of the REWIND population, which is better representation than many cardiovascular outcome trials but still not a sex-stratified primary endpoint.

PCOS in Reproductive Years

For women with PCOS, GLP-1 receptor agonists address several core features simultaneously: insulin resistance, appetite dysregulation, and weight. A 2023 meta-analysis in Fertility and Sterility found that GLP-1 receptor agonist use in women with PCOS was associated with significant reductions in body weight, fasting insulin, and testosterone levels compared to placebo, with a favorable safety profile. Dulaglutide was included in some of the constituent trials.

Pregnancy, Lactation, and Contraception: Non-Negotiable Information for Women on Trulicity

This section is required reading if you are on dulaglutide and are of reproductive age, trying to conceive, pregnant, or breastfeeding.

Pregnancy: Dulaglutide Is Contraindicated

Dulaglutide is classified as FDA Pregnancy Category not assigned under the newer labeling system, but the Trulicity prescribing information states that dulaglutide should be discontinued when pregnancy is detected. Animal studies showed adverse effects on fetal development at clinically relevant exposures. Human data are limited. There is no established safe dose in pregnancy.

If you are planning to conceive, you should stop dulaglutide at least two months before attempting conception. This washout period accounts for the drug's half-life (approximately five days) and gives adequate time to confirm the drug is cleared before implantation.

Unplanned pregnancy is a real consideration. Women with PCOS, who are frequently prescribed GLP-1 agents, often have irregular cycles that make pregnancy difficult to detect early. If there is any chance you could be pregnant, take a test promptly and contact your prescriber.

Lactation: Unknown Transfer, Generally Avoided

Human data on dulaglutide transfer into breast milk do not exist in sufficient quantity to make a safety determination. The prescribing information advises that the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need and any potential adverse effects on the infant. Given the lack of data and the availability of alternative diabetes treatments with established lactation safety profiles, most clinicians recommend stopping dulaglutide during breastfeeding and resuming postweaning.

Contraception Requirements

If you are sexually active and not planning pregnancy, use effective contraception while taking dulaglutide. As noted above, the drug's effect on gastric emptying may theoretically reduce peak concentration of oral contraceptives, though the clinical significance has not been fully characterized. Long-acting reversible contraception (IUD or implant) eliminates this interaction concern entirely and is worth discussing with your prescriber if you are on oral pills.

Women with PCOS who are using dulaglutide specifically to improve ovulatory function should be aware that successful treatment may restore ovulation in previously anovulatory cycles, increasing pregnancy risk. Do not assume that a history of irregular periods means you cannot conceive while on this medication.

Who Trulicity Is Right For, and Who Should Consider Alternatives

Women Most Likely to Benefit

• Women with type 2 diabetes who have not achieved glycemic targets on metformin alone
• Women with established cardiovascular disease or high cardiovascular risk, given the REWIND trial outcomes data
• Women with PCOS and significant insulin resistance where metformin is not adequate
• Perimenopausal women with type 2 diabetes and weight-related metabolic disease, after a thorough risk-benefit discussion
• Women who prefer a once-weekly injection over a daily medication

Women Who Should Consider Alternatives

• Women who are pregnant or planning pregnancy within the next two to three months
• Women currently breastfeeding, unless no safer alternative exists and the prescriber has reviewed the risk-benefit carefully
• Women with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), as dulaglutide carries an FDA black box warning for this risk
• Women whose primary goal is weight loss without diabetes: dulaglutide is not FDA-approved for this indication, and semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound) may be more appropriate and may have better insurance coverage for weight management
• Women with a history of pancreatitis or severe gastroparesis

Frequently Asked Questions